Terumo Aortic Announces Launch of Landmark Global Surgical Graft Study

September 21, 2021

Terumo Aortic today announced the launch of the company's global surgical graft study known as PANTHER. This study is a prospective and retrospective, multi-centre, multi-arm, post-market study of the company's comprehensive range of knitted and woven surgical grafts and cardiovascular patches.

The PANTHER study is the first of its kind in the world and represents a significant commitment to the extensive collection of data on the company's open surgical grafts and cardiovascular patches across a large number of geographies. One of the key aims of the study is to demonstrate the long-term clinical performance of open surgical grafts.

The study will start with over 30 sites at leading healthcare institutions primarily in Europe and North America. There are five defined cohorts as outlined in the study protocol with each group representing a specific product family; approximately 900 patients will be enrolled and followed for more than 10 years. Future expansion of the study to include new products is anticipated bringing total enrolment to over 1500 patients.

Lijckle van der Laan, MD, PhD, Vascular Surgeon, Department of Surgery, Amphia Hospital, The Netherlands and visiting Professor at Department of Cardiovascular Science KU Leuven in Belgium, enrolled the first patient in Europe and commented: "The PANTHER study is an exciting opportunity to gather long-term follow-up data on surgical grafts used to treat a wide range of cardiothoracic and vascular pathologies. I'm not aware of this type of data having been recorded previously in relation to the scope of this study and it will provide physicians with a far better understanding of the clinical behaviour of these surgical grafts."

In the United States, Principal Investigator, Daniel Newton, MD, Assistant Professor of Surgery, Virginia Commonwealth University School of Medicine, Virginia, US added: "We are delighted to have enrolled the first patient in the US. We look forward to contributing to this global study and collecting data on grafts and patches implanted for open surgery. To date, the majority of studies on surgical grafts are limited to short-term follow-up and the study will be a significant step towards understanding long-term outcomes."

Jeffrey Mifek, Global Vice President, Clinical and Medical Affairs at Terumo Aortic said: "PANTHER is a landmark study for the company and we are hoping that the insights from the data collated in the coming years will serve to provide the global surgical community with substantial information helping to shape future treatment options for patients. Terumo Aortic is committed to building clinical evidence that supports the entire aortic solutions portfolio."

About Terumo Aortic

At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable device portfolio through the development of digital technologies.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Media Contact

Corporate Communication Dept., Terumo Corporation

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.

Print
T
O
P